Literature DB >> 23899507

Expression at a 20L scale and purification of the extracellular domain of the Schistosoma mansoni TSP-2 recombinant protein: a vaccine candidate for human intestinal schistosomiasis.

Elena Curti1, Clifford Kwityn, Bin Zhan, Portia Gillespie, Jill Brelsford, Vehid Deumic, Jordan Plieskatt, Wanderson C Rezende, Eric Tsao, Bose Kalampanayil, Peter J Hotez, Maria Elena Bottazzi.   

Abstract

A novel recombinant protein vaccine for human schistosomiasis caused by Schistosoma mansoni is under development. The Sm-TSP-2 schistosomiasis vaccine is comprised of a 9 kDa recombinant protein corresponding to the extracellular domain of a unique S. mansoni tetraspanin. Here, we describe the cloning and the expression of the external loop of Sm-TSP-2 recombinant protein secreted by Pichia Pink the process development at 20L scale fermentation, and the two-steps purification, which resulted in a protein recovery yield of 31% and a protein purity of 97%. The developed processes are suitable for the production of purified protein for subsequent formulation and Phase 1 clinical studies.

Entities:  

Keywords:  Pichia Pastoris; Schistosoma mansoni; Schistosomiasis; Sm-TSP-2; neglected tropical diseases; recombinant protein; vaccine

Mesh:

Substances:

Year:  2013        PMID: 23899507      PMCID: PMC3981843          DOI: 10.4161/hv.25787

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  31 in total

Review 1.  Schistosomiasis.

Authors:  Allen G P Ross; Paul B Bartley; Adrian C Sleigh; G Richard Olds; Yuesheng Li; Gail M Williams; Donald P McManus
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

2.  Proteins exposed at the adult schistosome surface revealed by biotinylation.

Authors:  Simon Braschi; R Alan Wilson
Journal:  Mol Cell Proteomics       Date:  2005-11-03       Impact factor: 5.911

Review 3.  Schistosome membrane proteins as vaccines.

Authors:  Alex Loukas; Mai Tran; Mark S Pearson
Journal:  Int J Parasitol       Date:  2006-12-28       Impact factor: 3.981

4.  Synthesis and spectroscopic observation of dendrimer-encapsulated gold nanoclusters.

Authors:  M Linh Tran; Andrei V Zvyagin; Taras Plakhotnik
Journal:  Chem Commun (Camb)       Date:  2006-05-03       Impact factor: 6.222

Review 5.  Human schistosomiasis.

Authors:  Bruno Gryseels; Katja Polman; Jan Clerinx; Luc Kestens
Journal:  Lancet       Date:  2006-09-23       Impact factor: 79.321

6.  Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis.

Authors:  Mai H Tran; Mark S Pearson; Jeffrey M Bethony; Danielle J Smyth; Malcolm K Jones; Mary Duke; Tegan A Don; Donald P McManus; Rodrigo Correa-Oliveira; Alex Loukas
Journal:  Nat Med       Date:  2006-06-18       Impact factor: 53.440

Review 7.  Schistosomiasis: from risk assessment to control.

Authors:  Nils Robert Bergquist
Journal:  Trends Parasitol       Date:  2002-07

8.  Development of antibody isotype responses to Schistosoma mansoni in an immunologically naive immigrant population: influence of infection duration, infection intensity, and host age.

Authors:  C W Naus; G Kimani; J H Ouma; A J Fulford; M Webster; G J van Dam; A M Deelder; A E Butterworth; D W Dunne
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

9.  Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis.

Authors:  Gilles Riveau; Dominique Deplanque; Franck Remoué; Anne-Marie Schacht; Hubert Vodougnon; Monique Capron; Michel Thiry; Joseph Martial; Christian Libersa; André Capron
Journal:  PLoS Negl Trop Dis       Date:  2012-07-03

10.  Neglected tropical diseases in sub-saharan Africa: review of their prevalence, distribution, and disease burden.

Authors:  Peter J Hotez; Aruna Kamath
Journal:  PLoS Negl Trop Dis       Date:  2009-08-25
View more
  11 in total

1.  Still hope for schistosomiasis vaccine.

Authors:  Alessandra Ricciardi; Momar Ndao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Non-conventional expression systems for the production of vaccine proteins and immunotherapeutic molecules.

Authors:  Isabelle Legastelois; Sophie Buffin; Isabelle Peubez; Charlotte Mignon; Régis Sodoyer; Bettina Werle
Journal:  Hum Vaccin Immunother       Date:  2016-12-01       Impact factor: 3.452

3.  Recombinant Opisthorchis viverrini tetraspanin expressed in Pichia pastoris as a potential vaccine candidate for opisthorchiasis.

Authors:  Luyen Thi Phung; Sujittra Chaiyadet; Nuttanan Hongsrichan; Javier Sotillo; Hang Dinh Thi Dieu; Canh Quang Tran; Paul J Brindley; Alex Loukas; Thewarach Laha
Journal:  Parasitol Res       Date:  2019-11-14       Impact factor: 2.289

4.  A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area.

Authors:  W A Keitel; G E Potter; D Diemert; J Bethony; H M El Sahly; J K Kennedy; S M Patel; J L Plieskatt; W Jones; G Deye; M E Bottazzi; P J Hotez; R L Atmar
Journal:  Vaccine       Date:  2019-09-09       Impact factor: 3.641

Review 5.  Eliminating Schistosomes through Vaccination: What are the Best Immune Weapons?

Authors:  Cristina Toscano Fonseca; Sergio Costa Oliveira; Clarice Carvalho Alves
Journal:  Front Immunol       Date:  2015-03-09       Impact factor: 7.561

6.  Impact of Schistosoma mansoni on malaria transmission in Sub-Saharan Africa.

Authors:  Martial L Ndeffo Mbah; Laura Skrip; Scott Greenhalgh; Peter Hotez; Alison P Galvani
Journal:  PLoS Negl Trop Dis       Date:  2014-10-16

Review 7.  Schistosomiasis vaccines: where do we stand?

Authors:  Biniam Mathewos Tebeje; Marina Harvie; Hong You; Alex Loukas; Donald P McManus
Journal:  Parasit Vectors       Date:  2016-09-30       Impact factor: 3.876

8.  Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate.

Authors:  Wen-Hsiang Chen; Shivali M Chag; Mohan V Poongavanam; Amadeo B Biter; Ebe A Ewere; Wanderson Rezende; Christopher A Seid; Elissa M Hudspeth; Jeroen Pollet; C Patrick McAtee; Ulrich Strych; Maria Elena Bottazzi; Peter J Hotez
Journal:  J Pharm Sci       Date:  2017-04-26       Impact factor: 3.534

9.  Process Characterization and Biophysical Analysis for a Yeast-Expressed Phlebotomus papatasi Salivary Protein (PpSP15) as a Leishmania Vaccine Candidate.

Authors:  Wen-Hsiang Chen; Mun Peak Nyon; Mohan V Poongavanam; Zhuyun Liu; Amadeo B Biter; Rakhi T Kundu; Ulrich Strych; Peter J Hotez; Maria Elena Bottazzi
Journal:  J Pharm Sci       Date:  2020-02-15       Impact factor: 3.534

Review 10.  Eliminating the Neglected Tropical Diseases: Translational Science and New Technologies.

Authors:  Peter J Hotez; Bernard Pecoul; Suman Rijal; Catharina Boehme; Serap Aksoy; Mwelecele Malecela; Roberto Tapia-Conyer; John C Reeder
Journal:  PLoS Negl Trop Dis       Date:  2016-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.